Aliyah Pabani
- Co-authors
- Justin F. GainorNaiyer A. RizviMichael LanutiCodruța ChiuzanCatherine A. ShuMark M. AwadSimon K. ChengJoshua Sonett
- Topics
- Lung Cancer Treatments and Mutations (20 papers)Cancer Immunotherapy and Biomarkers (16 papers)Lung Cancer Research Studies (9 papers)
- Partner nations
- CanadaUnited StatesDenmark
In The Last Decade
Aliyah Pabani
27 papers receiving 807 citations
Hit Papers
Peers
Comparison fields: 5 of 65
- Oncology 629
- Pulmonary and Respiratory Medicine 533
- Surgery 86
- Immunology 82
- Molecular Biology 80
Countries citing papers authored by Aliyah Pabani
This map shows the geographic impact of Aliyah Pabani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aliyah Pabani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aliyah Pabani more than expected).
Fields of papers citing papers by Aliyah Pabani
This network shows the impact of papers produced by Aliyah Pabani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aliyah Pabani. The network helps show where Aliyah Pabani may publish in the future.
Co-authorship network of co-authors of Aliyah Pabani
This figure shows the co-authorship network connecting the top 25 collaborators of Aliyah Pabani. A scholar is included among the top collaborators of Aliyah Pabani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aliyah Pabani. Aliyah Pabani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 0 | |
| 3 | 1 | |
| 4 | Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitorsbreakdown → | 60 |
| 5 | 14 | |
| 6 | 2 | |
| 7 | 0 | |
| 8 | 2 | |
| 9 | 14 | |
| 10 | 7 | |
| 11 | 13 | |
| 12 | 5 | |
| 13 | 14 | |
| 14 | 2 | |
| 15 | 4 | |
| 16 | 1 | |
| 17 | 32 | |
| 18 | 2 | |
| 19 | Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trialbreakdown → | 425 |
| 20 | 17 |
About Aliyah Pabani
Aliyah Pabani is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Applied Microbiology and Biotechnology, having authored 32 papers that have together received 814 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (20 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Lung Cancer Research Studies (9 papers). The work is most often cited by research in Oncology (629 citations), Pulmonary and Respiratory Medicine (533 citations) and Health Informatics (6 citations). Aliyah Pabani has collaborated with scholars based in Canada, United States and Denmark. Frequent co-authors include Justin F. Gainor, Naiyer A. Rizvi, Michael Lanuti, Codruța Chiuzan, Catherine A. Shu, Mark M. Awad, Simon K. Cheng, Joshua Sonett, Anjali Saqi and Mark Stoopler. Their work appears in journals such as Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.